Enanta Pharmaceuticals (ENTA) Lifted to Buy at BidaskClub

BidaskClub upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a buy rating in a research note released on Tuesday morning.

A number of other research analysts also recently weighed in on the company. JMP Securities restated a buy rating and issued a $120.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, July 31st. Zacks Investment Research upgraded Enanta Pharmaceuticals from a hold rating to a buy rating and set a $126.00 price target for the company in a research note on Wednesday, July 25th. UBS Group downgraded Enanta Pharmaceuticals from an outperform rating to a market perform rating in a research note on Wednesday, August 8th. Oppenheimer set a $100.00 price target on Enanta Pharmaceuticals and gave the company a hold rating in a research note on Tuesday, August 14th. Finally, ValuEngine downgraded Enanta Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, November 8th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $104.00.

ENTA stock opened at $78.94 on Tuesday. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of 86.75 and a beta of 1.04. Enanta Pharmaceuticals has a twelve month low of $45.14 and a twelve month high of $127.77.

In other news, insider Tim Ocain sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $83.64, for a total value of $2,091,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Nathalie Adda sold 4,155 shares of the firm’s stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $95.32, for a total value of $396,054.60. Following the completion of the sale, the vice president now directly owns 4,155 shares of the company’s stock, valued at $396,054.60. The disclosure for this sale can be found here. Company insiders own 10.56% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. United Services Automobile Association lifted its position in shares of Enanta Pharmaceuticals by 1.7% in the second quarter. United Services Automobile Association now owns 37,289 shares of the biotechnology company’s stock valued at $4,322,000 after buying an additional 635 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Enanta Pharmaceuticals by 7.8% in the second quarter. State Board of Administration of Florida Retirement System now owns 8,849 shares of the biotechnology company’s stock valued at $1,026,000 after buying an additional 640 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Enanta Pharmaceuticals by 22.6% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 3,747 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 690 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Enanta Pharmaceuticals by 1.9% in the second quarter. Rhumbline Advisers now owns 37,550 shares of the biotechnology company’s stock valued at $4,352,000 after buying an additional 691 shares during the last quarter. Finally, Strs Ohio lifted its position in shares of Enanta Pharmaceuticals by 7.4% in the third quarter. Strs Ohio now owns 11,600 shares of the biotechnology company’s stock valued at $991,000 after buying an additional 800 shares during the last quarter. 78.72% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Recommended Story: Understanding Price to Earnings Ratio (PE)

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply